论文部分内容阅读
目的采用９９ｍＴＣ＿ＭＩＢＩ直肠门脉显影法测定心肝核素显影比（Ｈ／Ｌ比值）评估普鲁纳洛治疗门脉高压的疗效．方法肝硬变门脉高压患者在普鲁纳洛治疗前后均进行９９ｍＴＣ＿ＭＩＢＩ直肠门脉显影测定，并与对照组结果进行比较分析．结果肝硬变门脉高压者Ｈ／Ｌ显著高于对照组（０．１４±００５，ｎ＝１０，Ｐ＜００１）；肝硬变门脉高压组于普鲁纳洛治疗后Ｈ／Ｌ组较治疗前降低，差异显著（ｎ＝１４，０．５６±０．２２，０．７７±０．２６，Ｐ＝０．０２５）；Ｈ／Ｌ比值＜０．６者曲张静脉破裂出血无复发．结论普鲁纳洛预防肝硬变门脉高压者的曲张静脉破裂出血安全、有效；９９ｍ＿ＴＣ＿Ｍ１Ｂ１直肠门脉显影可作为普鲁纳洛治疗疗效观察的可靠的无创伤性的指标．
Objective To evaluate the efficacy of Prunella in the treatment of portal hypertension by using 99mTC_MIBI rectal portal imaging to determine the ratio of H / L development (H / L ratio). Methods Patients with cirrhosis were treated with Prometazole for 99mTC_MIBI rectal portal imaging before and after treatment, and compared with the control group. Results The H / L of cirrhotic patients with portal hypertension was significantly higher than that of the control group (0.14 ± 005, n = 10, P <001). In cirrhotic patients with portal hypertension, H / L group than before treatment, the difference was significant (n = 14,0.56 ± 0.22,0.77 ± 0.26, P = 0.025); H / L ratio <0.6 were varicose vein No recurrence of rupture bleeding. Conclusions Prunello is safe and effective in preventing variceal bleeding in cirrhotic patients with portal hypertension. 99m_TC_M1B1 rectal portal venography can be used as reliable noninvasive indicator of the efficacy of Prunella.